Company / PP&E (Net)
Dianthus Therapeutics, Inc. /DE/ PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$296.0K
FY2025
5-year range
$142.0K / $7.5M
FY2021-FY2025
Trend
+52.6%
vs FY2024
Sector context
#176 of 193
Health Care
What the data says
Among 193 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the bottom 9% for pp&e (net). PP&E (Net) has increased for 3 consecutive years, from $142,000 in FY2022 to $296,000 in FY2025.
Based on SEC 10-K filings.
$296,000 in FY2025 with a 5-year CAGR of -48.7%.
Improved from $185,000 to $296,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +27.7%
- 5-Year CAGR
- -48.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 193This company $296.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of -48.7%, indicating a declining trend.
- In FY2025, pp&e (net) increased 52.6% year-over-year.
- Ranks #176 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $296.0K | +52.6% |
| FY2024 | $194.0K | +4.9% |
| FY2023 | $185.0K | +30.3% |
| FY2022 | $142.0K | -98.1% |
| FY2021 | $7.5M | -10.2% |
| FY2020 | $8.3M | -16.0% |
| FY2019 | $9.9M | -3.1% |
| FY2018 | $10.2M | +422.1% |
| FY2017 | $2.0M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026